Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested Capital

Denali Therapeutics (DNLI) Equity Average (2018 - 2026)

Denali Therapeutics has reported Equity Average over the past 8 years, most recently at $970.0 million for Q4 2025.

  • Quarterly Equity Average fell 23.87% to $970.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $970.0 million through Dec 2025, down 23.87% year-over-year, with the annual reading at $1.1 billion for FY2025, 0.76% down from the prior year.
  • Equity Average was $970.0 million for Q4 2025 at Denali Therapeutics, down from $976.6 million in the prior quarter.
  • Over five years, Equity Average peaked at $1.4 billion in Q2 2024 and troughed at $847.9 million in Q3 2022.
  • The 5-year median for Equity Average is $1.1 billion (2023), against an average of $1.1 billion.
  • Year-over-year, Equity Average surged 139.94% in 2021 and then dropped 27.81% in 2025.
  • A 5-year view of Equity Average shows it stood at $987.3 million in 2021, then decreased by 6.12% to $926.9 million in 2022, then increased by 15.94% to $1.1 billion in 2023, then increased by 18.56% to $1.3 billion in 2024, then dropped by 23.87% to $970.0 million in 2025.
  • Per Business Quant, the three most recent readings for DNLI's Equity Average are $970.0 million (Q4 2025), $976.6 million (Q3 2025), and $1.1 billion (Q2 2025).